European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS

Prevention of SARS-CoV-2 infection through development and clinical testing of a novel Virus Like Particle (VLP) vaccine

Description du projet

Un nouveau vaccin contre le virus du SRAS-CoV-2

La course au développement d’un vaccin contre le virus du SRAS-CoV-2 est en cours. Le projet Prevent-nCoV, financé par l’UE, utilisera une technologie exclusive pour développer un vaccin nouveau et évolutif dont l’efficacité a été prouvée dans un modèle animal. La technologie combine de manière unique des pseudo-particules virales (PPV) et l’antigène de choix produit par n’importe quel système d’expression. Les deux composants sont mélangés dans des conditions physiologiques, conduisant à l’affichage à haute densité de l’antigène sur la surface PPV. Les vaccins candidats seront initialement testés pour leur capacité de neutralisation virale in vitro et dans des modèles d’infection précliniques avant de procéder à une étude de phase I/IIa.

Objectif

Our aim is to perform pre-clinical and clinical evaluation of a potential Wuhan Coronavirus vaccine candidate. The vaccine will be based on Virus-Like Particle (VLP) display of the SARS-CoV-2 Spike protein antigen. AdaptVac's VLP display technology has been shown to significantly improve vaccine immunogenicity, longevity and efficacy, for a wide range of viral and parasite diseases in pre-clinical studies (including flu and malaria). A unique feature of the technology is its two-component approach. The VLP is generic to all vaccines, and produced at >1g/L yields using E. coli. The disease antigen is produced in any expression system, allowing the most challenging antigens to be successfully produced. The VLP and antigen is then simply mixed, and a spontaneous, irreversible, conjugation
occurs under physiological conditions. This results in site-specific, directional, and high-density display of the antigen on the VLP surface. The antigen will be produced using ExpreS2ion's Drosophila S2 insect cells based on the trimetric spike antigen. Furthermore, E. coli and baculovirus will be tested for Spike protein variants. The vaccine candidates will be tested pre-clinically using in vitro viral neutralization assays and possibly animal challenge
models as they become available at LUMC. ExpreS2ion will develop the production processes and transfer these for GMP manufacture of the VLP and vaccine antigen, outsourced, to AGC Biologics. Finally, a phase I/IIa study will be performed at Radboud University Medical Center in the Netherlands. A surrogate marker of protection will be established by showing protection in animal models using passive transfer of participant sera, or by in vitro SARS-CoV-2 viral neutralization. This project is focused on delivering a scalable vaccine, ready for testing in the field, which has been shown to be safe in humans and effective in in vitro or animal models.

Coordinateur

KOBENHAVNS UNIVERSITET
Contribution nette de l'UE
€ 128 647,50
Adresse
NORREGADE 10
1165 Kobenhavn
Danemark

Voir sur la carte

Région
Danmark Hovedstaden Byen København
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
€ 128 647,50

Participants (8)